DMPK and myeloid sarcoma: Such promising findings, together with the good in silico and in vivo DMPK properties of compound 9, led us to eventually test it in EAE mice, a model resembling several clinical features of human MS and the most credited model for testing the efficacy of disease modifying compounds [34].